Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Political Reporter Online.
Press releases published on July 30, 2025
Argent LNG Ignites Talent Search to Power Next-Generation LNG Export Terminal at Port Fourchon
EIN Presswire
·
July 30, 2025
METAIRIE, LA, UNITED STATES, July 30, 2025 /EINPresswire.com/ -- Argent LNG, a trailblazing U.S. LNG developer committed to delivering cleaner, reliable energy to nations of shared values, today announced the launch of a strategic talent acquisition …
University students develop a project that brings Islamic artifacts to life through Augmented Reality
EIN Presswire
·
July 30, 2025
A student-developed Augmented Reality project brings the marvels of Islamic art and heritage directly to our mobile phones SHARJAH, EMIRATE OF SHARJAH, UNITED ARAB EMIRATES, July 30, 2025 /EINPresswire.com/ -- By Ifath Arwah Students from the College …
Viomi Technology Co., Ltd Granted Exception by Nasdaq Staff Regarding Form 20-F Filing
GlobeNewswire
·
July 30, 2025
GUANGZHOU, China, July 30, 2025 (GLOBE NEWSWIRE) -- Viomi Technology Co., Ltd (“Viomi” or the “Company”) (NASDAQ: VIOT), a leading technology company for home water solutions in China, today announced that it has been granted an exception by the Nasdaq …
Wolters Kluwer 2025 Half-Year Report
GlobeNewswire
·
July 30, 2025
Wolters Kluwer 2025 Half-Year Report Alphen aan den Rijn, July 30, 2025 – Wolters Kluwer, a global leader in professional information solutions, software and services, today releases its half-year 2025 results. Highlights Guidance for 2025 updated. (See …
AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML
GlobeNewswire
·
July 30, 2025
PRESS RELEASE AB SCIENCE RECEIVES REGULATORY APPROVAL FROM EUROPEAN COUNTRIES TO INITIATE THIRD STAGE OF PHASE I/II STUDY COMBINING ITS MOLECULE AB8939 WITH VENETOCLAX FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA THE COMBINATION OF AB8939 TARGETING …
AB Science a reçu l’approbation règlementaire de pays européens pour initier la troisième étape de la phase I/II visant à combiner sa molécule AB8939 avec le venetoclax dans le traitement de la LMA
GlobeNewswire
·
July 30, 2025
COMMUNIQUÉ DE PRESSE AB SCIENCE A RECU L’APPROBATION REGLEMENTAIRE DE PAYS EUROPEENS POUR INITIER LA TROISIEME ETAPE DE LA PHASE I/II VISANT A COMBINER SA MOLÉCULE AB8939 AVEC LE VENETOCLAX DANS LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË LA COMBINAISON D’ …
Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
GlobeNewswire
·
July 30, 2025
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Proposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 billion biosimilar market opportunity over next 10 years …
Communiqué de presse: Le SAR446523 de Sanofi, un anticorps monoclonal anti-GPRC5D, se voit accorder la désignation médicament orphelin pour le myélome multiple aux États-Unis
GlobeNewswire
·
July 30, 2025
Le SAR446523 de Sanofi, un anticorps monoclonal anti-GPRC5D, se voit accorder la désignation médicament orphelin pour le myélome multiple aux États-Unis Désignation accordée pour l’anticorps monoclonal GPRC5D à base d’immunoglobulines G pour le traitement …
Press Release: Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
GlobeNewswire
·
July 30, 2025
Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment of patients with relapsed or refractory multiple …
Nexans announces the departure of its Deputy Chief Executive Officer and Chief Financial Officer. The Company has initiated the search for a new Chief Financial Officer
GlobeNewswire
·
July 30, 2025
Nexans announces the departure of its Deputy Chief Executive Officer and Chief Financial Officer. The Company has initiated the search for a new Chief Financial Officer Paris, July 30th, 2025 — The Group announces today that Jean‑Christophe Juillard will …
Nexans annonce le départ de son Directeur Général Adjoint et Directeur Financier, et lance la recherche d’un successeur pour le poste de Directeur Financier
GlobeNewswire
·
July 30, 2025
Paris, le 30 juillet 2025 – Nexans annonce aujourd'hui que Jean-Christophe Juillard quittera ses fonctions de Directeur Général Adjoint et Directeur Financier dans les prochains mois. Avec sa contribution, Nexans a significativement amélioré sa …
H1 2025: Outstanding delivery of Nexans’ model, 2025 guidance upgraded
GlobeNewswire
·
July 30, 2025
H1 2025: Outstanding delivery of Nexans’ model +4.9% organic growth driven by the performance of our Electrification businesses (+7.8% organic growth) Record EBITDA and ongoing margin improvements Lynxeo disposal successfully completed 2025 guidance …
S1 2025 : Excellente exécution du modèle de Nexans, perspectives 2025 revues à la hausse
GlobeNewswire
·
July 30, 2025
S1 2025 : Excellente exécution du modèle de Nexans Croissance organique de +4,9 % tirée par la performance de nos activités d'Électrification (croissance organique de +7,8 %) EBITDA record et poursuite de la progression des marges Cession de Lynxeo …
J-Star Holding Announces Pricing of $5.0 Million Initial Public Offering
GlobeNewswire
·
July 30, 2025
TAICHUNG CITY, Taiwan, July 29, 2025 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (“J-Star” or the “Company”), a leading provider of innovative carbon fiber and composite solutions across a wide range of applications including personal sports equipment, …